Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments: 2013-2024

Historic Long-Term Investments for Agios Pharmaceuticals (AGIO) over the last 12 years, with Dec 2024 value amounting to $638.3 million.

  • Agios Pharmaceuticals' Long-Term Investments fell 53.60% to $304.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.3 million, marking a year-over-year decrease of 53.60%. This contributed to the annual value of $638.3 million for FY2024, which is 2068.58% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Long-Term Investments stood at $638.3 million for FY2024, which was up 2,068.58% from $29.4 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Long-Term Investments peaked at $638.3 million during FY2024, and registered a low of $29.4 million during FY2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Long-Term Investments value was $313.9 million (recorded in 2022), while the average stood at $327.2 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Long-Term Investments plummeted by 90.62% in 2023, and later spiked by 2,068.58% in 2024.
  • Agios Pharmaceuticals' Long-Term Investments (Yearly) stood at $97.6 million in 2020, then surged by 172.90% to $266.4 million in 2021, then climbed by 17.83% to $313.9 million in 2022, then slumped by 90.62% to $29.4 million in 2023, then spiked by 2,068.58% to $638.3 million in 2024.